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Abstract: Many studies have established the therapeutic benefits of angiotensin-converting enzyme (ACE) inhibitors such as reducing
reperfusion arrhythmias, and angiotensin II type 1 (AT1) blocker may have similar effects to ACE inhibitors. In this study, it was
aimed to compare the effects of an ACE inhibitor captopril and AT1 receptor blocker losartan on death from arrhythmias and
biochemical markers such as cardiac troponin T and I (cTnT, cTnI), myoglobin, creatin kinase (CK), creatine kinase-MB isoenzyme
(CK-MB) and aspartate aminotransferase (AST) after cardiac ischemia/reperfusion in an in vivo rat model. Study design and methods:
sixty four male rats were divided into four groups: Control, captopril (3 mg/kg), losartan (2 mg/kg) and sham. The drugs were
administered intravenously 10 min before ischemia under anesthesia. Except for the sham group, the left coronary artery was
occluded for 7 min and followed by 10 the min of reperfusion. Blood pressure, heart rate and ECG were monitored throughout the
experiment. Biochemical markers were evaluated from the blood samples obtained at the 10th min of reperfusion. Captopril
significantly decreased total ventricular fibrillation (VF) and death due to irreversible VF, while losartan did not. cTnT, myoglobin,
total CK and CK-MB levels were higher in the control and drug administered groups than in the sham group. cTnT and cTnI levels
were significantly increased after captopril administration in comparison with the control group, while losartan administration had
no effect. In conclusion, captopril is more effective than losartan, especially for decreasing death from irreversible VF. In addition,
captopril may increase the biochemical cardiac markers in the blood during early reperfusion.
Key Words: Myocardial Ischemia-Reperfusion, Arrhythima, Cardiac Marker, Troponin, Captopril, Losartan.

Introduction
Acute myocardial infarction (AMI) is a major public
health problem in the industrialized world and is
becoming an increasingly important problem also in the
developing countries. Occlusion of coronary arteries
induces myocardial changes from ischemia to infarction.
Prevention of myocardial infarction in ischemia is the
primary and immediate purpose of therapy. Reperfusion
may successfully prevent infarction development, but it
often exacerbates myocardial damages. Short-term
myocardial ischemia/reperfusion (I/R) leads to life
threatening arrhythmias in most species (1). Two main

factors concerned with reperfusion arrhythmias are free
oxygen radicals and cytosolic calcium overload, although
both factors may actually be acting together (2).
The classic World Health Organization (WHO) criteria
for the diagnosis of AMI include the history, typical
electrocardiographic changes and serum cardiac markers
such as creatine kinase (CK), the MB isoenzyme of
creatine kinase (CK-MB), myoglobin and cardiac specific
troponin T and I (cTnT and cTnI). Troponins exists in
different tissues and their levels increase in several clinical
conditions such as exercise, convulsions, intramuscular
injections, pulmonary embolism, trauma, e.g. (3-5), but

* This study was presented in the "17th National Congress of Pharmacology, 1st Clinical Pharmacology Symposium, Antalya, TURKEY, 17-21 October 2003".
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cTnT and cTnI are specific to myocardial cells.
Accordingly, detection of cardiac troponins in serum is
very important for detection of myocardial cellular injury.
Reperfusion of ischemic myocardium accelerates the
washout of intracellular proteins producing an
exaggerated and early peak value of substances (3).
Accumulating evidences support the therapeutic
benefits of angiotensin-converting enzyme (ACE)
inhibitors in many clinical conditions and experimental
studies such as hypertension, congestive heart failure.
They also limit infarct size and reduce reperfusion
arrhythmias in rats and dogs in vivo, additionally in
isolated rat heart and arrhythmias in post infarction heart
failure patients (6-11). ACE inhibitors have been shown
to attribute blockade of angiotensin II (Ang II) production
and decrease breakdown of bradykinin, which may
stimulate the production of prostaglandin and nitric oxide
(NO) (6,9,11). Ang II affects the target tissues by means
of Ang II receptors, and there are two types of these
receptors, AT1 and AT2. Most of the well-known Ang II
functions in the cardiovascular system are mediated
through AT1 (12). The clinical benefits of AT1 receptor
antagonists are thought to be similar to those of ACE,
and since they do not increase bradykinin, their cough
incidence is lower than ACE inhibitors (13). On the other
hand, in previous studies (6,11,14), the effect of AT1
antagonist losartan on cardiac I/R induced mortality has
been controversial.
The purpose of this study was to compare the effects
of ACE inhibitor captopril and AT1 receptor antagonist
losartan on cardiac I/R induced death due to irreversible
ventricular fibrillation (VF) and serum cardiac protein
elevations in an in vivo rat model.

Material and Methods
Animals and groups
In the experiment, 12 weeks old male Sprague
Dawley rats weighing 250-300 g were used. Animals
were housed two per cage in the animal quarter with an
alternating 12 h light-dark cycle, air-conditioned room
with 20-22 °C temperatures and they were given
standard rat pellet feed and water ad libitum. In the
experiments, “Guide for the Care and Use of Laboratory
Animals, DHEW Publication No. (NIH) 85-123, 1985”
regulations were followed.
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Rats were randomly divided into four groups: (1)
Sham operated (n = 10), (2) Control I/R; treated with
vehicle (0.09% NaCl, 1 ml/kg) (n = 18), (3) treated with
captopril (3 mg/kg; Sigma, USA) (n = 18) and (4) treated
with losartan (2 mg/kg; Merck, USA) (n = 18). Drugs and
vehicle were administered by intravenous (i.v.) injection
10 min before left coronary occlusion.

Experimental protocols
Male Sprague Dawley rats weighing 250–350 g were
anaesthetised with urethane 1.2–1.4 g/kg administered
intraperitoneally (i.p.). The jugular vein and trachea were
cannulated for drug administration and artificial
respiration with room air. Systemic blood pressure (BP)
was monitored from the carotid artery by a Harvard
model 50-8952 transducer (Harvard Apparatus Inc.,
South Natick, USA) and displayed on a Harvard model 609315 Universal oscillograph (Harvard Apparatus Inc.)
together with a standard ECG instrument.
The chest was opened by a left thoracotomy, followed
by sectioning the fourth and fifth ribs, about 2 mm to the
left of the sternum. Positive-pressure artificial respiration
was started immediately, using a volume of 1.5 ml/100 g
body weight at a rate 60 strokes/min to maintain normal
PCO2, PO2 and pH parameters.
After the pericardium was incised carefully, the heart
was exteriorized by gentle pressure on the right side of
the rib cage. A 6/0 silk suture attached to a 10 mm
micropoint reverse-cutting needle was quickly placed
under the left main coronary artery. The heart was then
carefully replaced in the chest, and the animal was
allowed to recover for 20 min. Any animal in which this
procedure produced arrhythmias or a sustained decrease
in blood pressure (BP) to less than 70 mmHg was
discarded.
The ligature was inserted through a small plastic tube
and the tube was placed in contact with the heart. The
artery could then be occluded by applying tension to the
ligature, and reperfusion was achieved by releasing the
tension.
The left coronary artery was occluded for 7 min and
then reperfused for a further 10 min before the
experiment was terminated. These durations of I/R and
number of rats were previously used in the same
experimental model successfully and it was reported that
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this protocol produced arrhythmic activity in optimum
number and severity [7]. ECG, BP and heart rate (HR)
were monitored before and during ischemia and 7 min
the after reperfusion period. Ventricular fibrillation and
discharge criteria were assessed according to the
diagnostic criteria advocated in the Lambeth conventions
[15]. At the end of the experiments, blood samples were
collected from the vena cava inferior, centrifuged for 10
min at 3000 r.p.m., and stored at –20 °C until
biochemical analysis.

Biochemical assays
All serum cardiac markers were measured with
autoanalyzers. Total CK, CK-MB and AST were
determined with Olympus System Reacent (OSR6179,
OSR6153 and OSR6109, respectively; Ireland). cTnT
concentration was measured with a Boehringer
Mannhaime analyzer (Germany). cTnI was quantitatively
determined with a Dianostic Products Corporation
analyzer (LKTI1; England). Myoglobin was determined
with a Roche analyzer (20753548, USA).

Statistical analysis
Differences in the incidence of death from irreversible
VF were analyzed by Fisher’s exact test. Statistical
analyses for biochemical parameters and total VF
(reversible + irreversible) were carried out by analysis of
variance (ANOVA) followed by appropriate post hoc tests
including multiple comparison tests (LSD). Data were
expressed as means ± standard error (SE). All analyses
were made using the SPSS statistical software package
and probability value of less than 0.05 was accepted as
statistically significant.

Results
After left coronary artery occlusion, all rats exhibited
cardiac arrhythmias, such as ventricular ectopic beats,
ventricular tachycardia or VF. But, we evaluated only total
VF and death from irreversible VF. During the ischemic
period, VF and mortality were not observed in any of the
rats. In the sham group, no rat exhibit VF during the
experiments.
Seven of 18 (38.9%) control rats died due to
reperfusion induced irreversible VF (P < 0.05). Captopril
(5.6%) significantly reduced the incidence of irreversible
VF (P < 0.05), where as losartan (33.3%) did not affect
the incidence of irreversible VF. Besides, captopril
significantly reduced incidence of total VF (P < 0.05) but
losartan did not (Table 1, Figure 1).
Levels of cTnT, cTnI and myoglobin are shown in
Table 2, Figure 2 and Figure 3. In all the I/R groups, cTnT
and myoglobin values were significantly higher than the
sham group (P < 0.05). In additon, cTnT and cTnI values
of captopril group were significantly higher than the
control group at 10 min of reperfusion (P < 0.05).
Total CK, CK-MB and AST values are shown in Table
3 and Figure 4. Total CK and CK-MB values of all I/R
groups were significantly higher than that of sham group
(P < 0.05), while AST values was higher than the sham
group in only the captopril group. However, there were
no significant differences between the I/R groups.

Discussion
Although ACE inhibitors and/or AT1 receptor
antagonist can protect the myocardium against I/R injury,
the exact mechanisms of the effect have not yet been
characterized at the cellular level. Several investigators,

Table 1. Summary of total and irreversible ventricular fibrillation (VF) incidences. Ischemia/reperfusion (I/R)
Total VF incidence (%)
Groups

Irreversible VF incidence (%)

Ischemia

Reperfusion

Ischemia

Reperfusion

Control (I/R)

0

14/18 (77.8)

0

7/18 (38.9)

Captopril + I/R

0

7/18 (38.9) * #

0

1/18 (5.6) *

Losartan+ I/R

0

13/18 (72.2)

0

6/18 (33.3)

* P < 0.05 significantly different from control group,
# P < 0.05 significantly different from losartan group.
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*
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*

0
Total VF

Irreversible VF

Figure 1. Percentage incidence of total and irreversible ventricular
fibrillation (VF) in the reperfusion periods. *P < 0.05,
significantly different from control group.

using different ACE inhibitors, have demonstrated a
reduction in both incidence and mean duration of
malignant arrhythmias in a variety of different
experimental models (7,14). In hearts impaired by
ischemia, the renin-angiotensin and kallikrein-kinin
systems are activated, resulting in increased release of
angiotensin II and kinins, especially bradykinin (16). ACE

inhibitors inhibit the accumulation of angiotensin II and
accumulate bradykinin in the myocardium. Consequently,
antiarrhythmic effects of ACE inhibitor one attributed,
among other causes, to inhibition of angiotensin II
synthesis and preservation of bradykinin (17,18). Kinins
are known to be a potent stimulator of the release of
prostaglandins and NO from the endothelium (19,20).
So, bradykinin may protect the myocardium by its
vasodilator effect. Akula et al (21) demonstrated that the
cardioprotective role of bradykinin during experimental
myocardial infarction involves prostaglandins and nitric
oxide pathways. On the other hand, Kawabata et al (22)
was claimed that beneficial effects of ACE inhibitor and/or
AT1 receptor antagonist on myocardial I/R were not
dependent on NO synthesis. Divisova et al (23) showed
that long-term captopril treatment increased the energy
potential and had a beneficial effect on tolerance of the
isolated heart to ischemia. L-arginine added into the
perfusate potentiates the effect of captopril on the NO
signaling pathway. Besides, NO was demonstrated to
exhibit an inhibitory effect on neutrophils which play an

Table 2. 10th min of reperfusion serum cardiac troponin T, I and myoglobin levels in groups. Values mean ± S.E.M, ischemia / reperfusion (I/R)

Groups

Troponin T (ng/mL)

Troponin I (ng/mL)

Myoglobin (ng/mL)

b

0.23 ± 0.01

24.88 ± 2.99

b

4.26 ± 0.58

a

0.32 ± 0.03

44.00 ± 2.08

a

Captopril + I/R

8.12 ± 1.38

a,b

55.44 ± 6.57

a

Losartan + I/R

3.85 ± 0.48

a

43.67 ± 2.42

a

Sham

0.96 ± 0.08

Control (I/R)

0.70 ± 0.16

a,b

0.32 ± 0.02

a; P < 0.05 significantly different from sham group,
b; P < 0.05 significantly different from control group.

ab

Sham

Control (I/R)

Captopril+I/R

Losartan+I/R
ab

0.8

8
6

1

0.6
a

a

4

0.4

2

0.2

0

Troponin I (ng/ml)

Troponin T (ng/ml)

10

0
Troponin T (ng/ml)

Troponin I (ng/ml)

Figure 2. Serum cardiac specific troponin T and I concentrations after ischemia-reperfusion (I/R) procedure in rats. Mean ± S.E.M;
a: P < 0.05 significantly different from sham group; b: P < 0.05 significantly different from control group.
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oxygen radical formation, especially during reperfusion,
i.e. during reoxygenation, when the oxygen tension in the
cell increases. Under circumstances where NO synthesis is
enhanced within physiological limits, i.e. in captopril
treated rats, with sufficient substrate for NOS by the
addition of L-arginine during ischemia, the content of
radical forms of mitochondrial respiratory chain
compounds decreases, thus reducing the risk of
generation of toxic oxygen radicals (24).

a

Myoglobin (ng/ml)

60
a

a

50
40
30
20
10
0
Sham

Control (I/R)

Captopril+I/R

Losartan+I/R

Consistent with our findings, Ozer et al (11) indicated
that captopril more effectively prevents mortality
associated with irreversible VF. On the contrary, Butz et
al (25) claimed that losartan but not enalaprilate exerts
acute anti-arrhythmic effects during reperfusion. The
cardioprotective effect of AT1 antagonists during I/R
induced injury has been controversial. Harada et al (26)
found that both genetic deletion of the AT1a gene and
treatment with the AT1 antagonist CV-11974
significantly attenuate reperfusion arrhythmias.

Figure 3. Serum myoglobin concentration after ischemia-reperfusion
(I/R) procedure in rats. Mean ± S.E.M; a: P < 0.05
significantly different from sham group.

important role in myocardial I/R injury and/or platelet
aggregation. In addition, NO release would potentiate the
scavenging of superoxide which might contribute to the
myocardial protective effects of ACE inhibitors. The
ischemic situation of the myocardium may accelerate

Table 3.

10th min of reperfusion serum creatine kinase (CK), MB isoenzyme of creatine kinase (CK-MB) and aspartate amino transferase (AST)
levels. Values mean ± S.E.M, ischemia/reperfusion (I/R)

Groups

CK (U/L)

CK-MB (U/L)

AST (U/L)

Sham

1136.00 ± 23.30

b

828.62 ± 30.25

b

Control (I/R)

1321.87 ± 36.78

a

1097.75 ± 42.23

a

Captopril ± I/R

1353.44 ± 61.23

a

1112.78 ± 50.20

a

Losartan ± I/R

1311.33 ± 20.28

a

1104.72 ± 30.84

a

210.86 ± 8.01
277.75 ± 15.69
329.44 ± 29.44

a

266.78 ± 17.40

a; P < 0.05 significantly different from sham group,
b; P < 0.05 significantly different from control group.

1600
1400

Sham

Control (I/R)
a

a

Captopril+I/R

a

1200

Losartan+I/R

a
a

a

(U/L)

1000
800
600

a

400
200
0
CK

CK-MB

AST

Figure 4. Serum creatine kinase (CK), the MB isoenzyme of creatine kinase (CK-MB)
and the aspartat amino transferase (AST) levels after ischemia-reperfusion
(I/R) procedure in rats. Mean ± S.E.M; a: P < 0.05 significantly different
from sham group.
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Reperfusion induced arrhythmias are postulated to be
associated with major alterations in intracellular Ca2+
levels (27). However, the underlying mechanism of
calcium overload remains unknown. Angitensin II not only
increases Ca2+ influx through the L-type Ca2+ channel but
also induces Ca2+ release from intracellular stores through
AT1 (28). Accordingly, Ang II may play a major role in
calcium overload during reperfusion which is closely
related to the incidence of I/R arrhythmias (26). In
addition, Ang II is known to induce the release of
catecholamine, and catecholamine induces arrhythmia.
These mechanisms may also contribute to the beneficial
effects of ACE inhibitors on I/R induced irreversible VF.
Reperfusion of ischemic myocardium also accelerates
the washout of intracellular proteins “serum cardiac
markers”, producing an exaggerated and early peak value
of substances such as CK-MB and cTnT and cTnI (3,4).
Serum cardiac markers are performed to confirm the
myocardial injury seen in ECG and history. CK and AST
have proved to be too unselective for the detection of
myocardial injury at an early stage in rat. Although CKMB is more specific for myocardium than total CK, small
quantities of CK-MB isoenzyme are found in tissues other
than the heart. Myoglobin is the earliest serum marker in
the myocardial infarction but it has no cardiac specificity.
Moreover, high serum levels of myoglobin should be
supplemented by a more cardiac specific marker (1,29).
cTnT and cTnI have been shown to be highly sensitive and
specific markers of myocardial cell injury (4,29-32).
Cardiac troponins are not detected in the peripheral
circulation under normal circumstances. In patients with
AMI, cardiac troponins increase after myoglobin and
before the other markers of myocardial injury (1).

Recently, the utility of serum markers of cardiac damage
has improved dramatically. Fredericks et al (33)
confirmed that cTnT and cTnI are cardiac specific markers
of myocardial damage in certain common laboratory
animals such as rat, dog, pig and monkey. Vorderwinkler
et al (34) demonstrated that cTnT and cTnI levels reach
peak values in the rat heart perfusate at the 10th min of
the reoxygenation period. In this study, myoglobin and
cardiac troponin levels were significantly increased after
captopril administration in comparison with the control
group, while losartan administration had no effect.
However, captopril reduced mortality due to the
irreversible VF. The contrary finding may arise from the
fact that ACE inhibition increases kinin levels in
ischemia/reperfused myocardium. Thus, bradykinin
induced vasodilatation increases reperfused myocardium
and accelerates the washout of serum cardiac markers.
In conclusion; after short time cardiac I/R, a ACE
inhibitor captopril reduced VF incidence and mortality due
to the irreversible VF, whereas, AT1 receptor blocker
losartan had no effect on VF incidence and mortality. In
addition, captopril may increase serum cardiac markers in
the early reperfusion period.
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